Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Rare Diseases or Orphan Drugs

Back to categories

Judging criteria:

Excellence in creating market and customer insight and initiating new therapies for patients with rare diseases (15)

  • Demonstrate how you gained in-depth understanding of your market and customer (payer, physician and patient) needs

Clarity and appropriateness of SMART objectives (10)

  • Demonstrate how your objectives related to all stakeholders and reinforced each other

Quality of marketing strategy (15)

  • Demonstrate what specific insights led to your choice of the particular strategy
  • Evidence as to how payer/physician patient needs were addressed
  • Evidence of resource allocation decisions based on customers’ needs and value

Quality of execution (15)

  • Evidence of differentiated content being provided in a meaningful way to customers whether through an integrated multichannel programme or the effective use of specific channels
  • Evidence of customer engagement and positive supportive statements from stakeholders
  • Evidence of differentiation and enhanced value
  • Evidence of multifunctional working

Quality of measurement and learning (10)

  • Demonstrate how metrics have been applied to measure outcomes
  • Evidence of knowledge gained that will inform and shape future decision-making

Evidence of improved health outcomes (15)

  • Evidence of engagement and positive supportive statements from HCPs and/or patients
  • Evidence of changed HCP perceptions and behaviours that will or have delivered improved health outcomes
  • Programmes that create and demonstrate better clinical outcome and/or health economic value

This category relates to work in support of any drug for a rare disease or disorder or classified orphan drug at any phase of the product life cycle.

Entrants will need to demonstrate a thorough understanding
of the specific healthcare environment, show how they tailored their approach to the specific challenge of rare diseases/orphan drugs and show an appropriate approach to deliver value to stakeholders and so drive the business forward.

Judges are looking for evidence of true collaboration with patient groups and healthcare professionals/advocates.

Brands within the global markets, other European countries or UK are eligible.

The entry should relate to activities carried out between July 2018 and June 2020.

Back to categories

Sponsors

Key dates

Entry deadline 27 August 2020
Extended entry deadline 3 September 2020*
*additional fee applies
Judging Day 1 October 2020
Company of the Year Interviews 22 October 2020
PMEA Event 25 November 2020